testicular disease: A non-neoplastic or neoplastic disorder affecting the testis. Representative examples include torsion, infarction, germ cell tumor, sex cord-stromal tumor, lymphoma, and leukemia.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleonly males |
244368 |
2. Check conditionsNone |
244368 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
219 |
4. Check minimum number of eventsNone |
219 |
5. Include endpointsNone |
219 |
6. Filter based on genotype QC (FinnGen only) |
199 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Testicular dysfunction, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Testicular dysfunction
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1111 | - | 1111 |
| Only index persons | 1058 | - | 1058 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | - | 0.03 |
| Only index persons | 0.04 | - | 0.04 |
| Median age at first event (years) | |||
| Whole population | - | - | 39.11 |
| Only index persons | - | - | 39.11 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 199 | - | 199 |
| Unadjusted period prevalence (%) | 0.09 | - | 0.09 |
| Median age at first event (years) | 51.48 | - | 51.48 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 206
- Matched controls
- 2060
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
54.9
191.9
135
69
E29.9
ICD-10 Finland
Testicular dysfunction, unspecified
2114.5
169.3
141
*
E29.1
ICD-10 Finland
Testicular hypofunction
38.5
77.5
50
17
E29.8
ICD-10 Finland
Other testicular dysfunction
+∞
73.4
66
*
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
38.6
67.2
43
14
A55
ICPC
General and Unspecified, Local injection/infiltration
45.9
23.3
28
7
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
20.1
19
*
A50
ICPC
General and Unspecified, Medication/prescr/renewal
9.2
20.1
26
32
121
Kela drug reimbursment
Severe hypofunction of sexual glands
184.3
16.8
17
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
6.3
16.1
29
52
WVA30, ,
SPAT
5.8
14.6
29
57
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
11.6
11
*
G47.3
ICD-10 Finland
Sleep apnoea
2.8
11.1
86
425
Y28
ICPC
Limited function/disability (Y)
45.9
11.1
13
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
9.3
9.0
18
21
N02AX02
ATC
tramadol; systemic, rectal
2.3
8.0
104
630
R53
ICD-10 Finland
Malaise and fatigue
2.5
7.5
57
272
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.7
6.8
41
174
N03AX16
ATC
[U] pregabalin
2.4
6.6
51
244
G03GA01
ATC
chorionic gonadotrophin; parenteral
72.0
6.5
7
*
N45.9
ICD-10 Finland
Orchitis, epididymitis and epididymo-orchitis without abscess
4.1
6.4
18
47
-50
ICPC
Medication/prescr/renewal
7.4
6.3
14
20
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.3
6.1
60
318
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
74
70
15.94
72.46
2.1
1.6
5.69
4.88
u/l
0.40
63
57
151
394
11.61
66.03
6.4
2.2
13.48
15.41
nmol/l
2.63
151
374
172
1064
4.74
17.40
4.7
4.3
1.36
1.60
ug/l
1.27
165
970
26
46
6.32
14.54
2.3
1.3
183.48
173.80
pmol/l
0.16
26
46
143
844
3.27
14.13
4.3
3.8
24.95
21.57
%
1.00
50
328
118
636
3.00
13.50
3.1
2.7
0.64
0.72
ug/l
0.54
59
338
191
1471
5.10
10.13
5.0
3.9
1.82
1.91
mu/l
0.62
185
1369
101
613
2.27
7.66
2.0
1.9
92.31
94.54
pmol/l
0.21
61
335
113
723
2.25
7.49
6.0
9.6
1.21
1.20
mmol/l
1.77
99
643
45
195
2.67
7.14
2.1
1.7
3.42
3.61
mmol/l
0.44
35
132
37
151
2.77
6.57
7.4
7.7
—
—
—
0
0
163
1272
2.35
5.93
8.7
9.1
75.15
79.03
u/l
0.43
157
1233
134
980
2.05
5.61
5.6
6.8
6.59
6.86
mmol/l
0.74
128
947
30
119
2.78
5.59
6.1
2.6
67.54
73.11
ml/min/173m2
0.26
13
55
52
270
2.24
5.48
2.7
2.0
4.18
3.93
ratio
0.47
41
207
177
1482
2.38
4.65
18.6
17.7
13.43
13.35
%
0.40
177
1469
56
321
2.02
4.51
2.4
2.2
2.57
2.93
mg/l
0.68
51
282
62
369
1.97
4.49
1.8
1.5
17.91
19.09
nmol/l
0.32
57
323
62
374
1.94
4.30
1.2
1.4
0.66
0.84
u/ml
1.09
17
116
17
61
2.95
3.79
1.2
1.7
1.56
3.43
mg/l
0.89
12
45
124
956
1.75
3.67
8.9
11.2
4.27
4.17
e9/l
0.12
115
838
39
211
2.05
3.63
2.3
2.1
—
—
—
0
0
95
685
1.72
3.54
4.9
5.9
37.76
36.88
g/l
0.78
89
654
110
833
1.69
3.37
3.6
3.1
0.00
0.00
estimate
-0.00
25
168
19
78
2.58
3.32
1.3
1.2
33.02
134.57
u/ml
—
6
30
192
1727
2.64
3.27
19.1
14.1
25.20
24.29
mg/l
0.14
156
1405
69
466
1.72
3.20
2.7
2.6
396.83
371.69
umol/l
1.12
63
415
41
236
1.92
3.20
2.4
2.1
—
—
—
0
0
92
672
1.67
3.18
2.6
2.9
—
—
estimate
—
0
0
90
656
1.66
3.13
3.4
3.0
0.00
0.00
estimate
-0.00
24
146
77
541
1.68
3.07
3.9
4.7
6.10
9.45
mg/mmol
0.70
52
383
31
164
2.05
3.06
3.1
3.9
1.75
1.67
mmol/l
0.04
26
146
110
849
1.63
3.02
3.6
3.1
0.00
0.02
estimate
0.50
23
145
54
347
1.75
2.96
1.8
1.5
—
—
—
0
0
11
32
3.57
2.95
1.1
1.1
—
—
—
0
0
109
844
1.62
2.92
3.7
3.1
0.00
0.00
estimate
-0.00
25
164
65
447
1.66
2.77
3.8
2.8
0.35
0.43
e6/l
0.10
48
317
64
439
1.66
2.75
4.2
3.2
0.00
0.01
estimate
0.50
25
152
88
656
1.60
2.70
6.1
8.9
1.21
1.20
mmol/l
0.30
81
620
54
359
1.68
2.60
1.9
1.7
0.86
1.64
mg/l
1.52
44
270
182
1634
1.98
2.58
5.2
4.7
6.09
6.03
mmol/l
0.18
171
1534
184
1660
2.02
2.54
17.2
13.4
84.60
89.10
ml/min/173m2
2.21
175
1527
66
466
1.61
2.50
3.8
3.3
2.35
2.34
mmol/l
0.27
59
427
87
660
1.55
2.41
6.2
3.3
21.19
41.25
ng/l
1.69
63
431
145
1237
1.58
2.33
3.2
3.1
—
—
—
0
0
10
35
2.95
2.24
1.2
1.2
3.71
3.82
mmol/l
—
10
35
139
1180
1.55
2.23
4.6
3.9
8.08
8.81
mm/h
0.24
132
1120
192
1776
2.19
2.19
6.2
4.9
1.21
1.28
mmol/l
2.48
186
1687
67
490
1.54
2.15
2.8
2.7
0.00
0.00
estimate
-0.00
22
132
161
1420
1.61
2.12
4.1
3.8
54.00
54.84
u/l
0.05
155
1359
41
273
1.63
1.94
3.0
2.6
0.28
0.88
e6/l
1.92
20
137
186
1717
1.86
1.89
5.5
4.2
1.51
1.41
mmol/l
0.88
178
1628
16
81
2.06
1.80
1.9
5.1
94.96
95.08
ng/l
0.00
16
75
48
340
1.54
1.75
3.7
3.8
4155.16
462.32
ng/l
0.43
37
265
53
384
1.51
1.74
4.9
3.3
1.02
1.02
kg/l
0.39
35
245
14
68
2.14
1.74
2.0
2.9
—
—
—
0
0
91
739
1.41
1.65
1.7
2.1
1.62
1.50
mmol/l
0.56
77
633
37
254
1.56
1.55
3.0
2.7
0.25
0.52
e6/l
0.61
17
118
5
15
3.39
1.53
1.4
1.1
—
—
—
0
0
13
65
2.07
1.52
2.0
2.8
—
—
—
0
0
49
361
1.47
1.48
2.5
2.7
—
—
—
0
0
23
143
1.68
1.42
2.3
1.8
0.24
0.34
mg/l
0.48
15
70
15
83
1.87
1.35
2.3
1.2
—
—
—
0
0
5
18
2.82
1.29
5.4
5.0
—
—
—
0
0
56
436
1.39
1.25
4.0
3.2
919.57
793.39
ng/l
0.16
47
358
14
79
1.83
1.20
1.1
1.1
—
—
—
0
0
30
209
1.51
1.19
2.1
1.9
—
—
—
0
0
25
167
1.57
1.19
3.9
8.2
10.00
7.99
mmol/l
0.88
25
161
30
211
1.49
1.14
2.0
1.8
—
—
—
0
0
34
246
1.46
1.13
1.2
1.2
9.97
24.92
iu/ml
—
9
61
7
34
2.10
1.04
1.3
1.3
—
—
—
0
0
12
69
1.78
0.99
1.3
1.8
0.07
0.07
iu/ml
—
5
12
36
271
1.40
0.98
2.0
2.0
—
—
—
0
0
6
119
0.49
0.97
1.0
1.1
1.29
1.43
g/l
—
6
119
19
129
1.52
0.87
1.3
1.4
—
—
—
0
0
0
25
0.00
0.79
0.0
11.0
—
51.40
—
0
10
24
175
1.42
0.79
4.5
4.4
28.94
28.03
%
0.15
16
122
6
34
1.79
0.77
1.3
1.3
—
—
—
0
0
0
28
0.00
0.76
0.0
1.4
—
—
—
0
0
32
247
1.35
0.76
7.9
11.1
104.91
104.30
mmol/l
0.44
32
247
9
54
1.70
0.75
1.2
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
3.6
6.96
7.27
pmol/l
—
5
24
7
38
1.87
0.74
1.4
1.1
—
—
—
0
0
16
109
1.51
0.73
2.3
1.5
—
—
—
0
0
7
119
0.57
0.70
1.1
1.1
0.97
0.93
g/l
—
7
119
5
27
1.87
0.69
1.0
1.5
—
—
—
0
0
5
27
1.87
0.69
1.0
1.5
—
—
—
0
0
5
28
1.80
0.66
3.0
1.7
—
—
—
0
0
8
51
1.59
0.61
1.3
1.5
—
—
—
0
0
6
35
1.74
0.58
1.5
1.5
—
—
—
0
0
11
73
1.54
0.57
1.4
1.3
—
—
—
0
0
6
37
1.64
0.56
1.5
1.1
—
—
—
0
0
6
38
1.60
0.55
1.3
1.2
—
—
—
0
0
26
209
1.28
0.49
1.3
1.2
1.26
5.10
u/ml
1.07
18
85
7
47
1.51
0.48
1.7
1.3
—
—
—
0
0
6
44
1.37
0.34
1.3
1.5
—
—
—
0
0
6
44
1.37
0.34
1.5
1.5
—
—
—
0
0
12
93
1.31
0.30
1.8
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
1.67
—
0
11
0
10
0.00
0.21
0.0
3.4
—
1.10
—
0
10
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
0.57
—
0
12
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
9
111
0.80
0.20
5.1
18.7
16.80
16.38
%
—
9
105
0
14
0.00
0.20
0.0
1.1
—
13.06
—
0
14
14
163
0.85
0.18
5.9
2.8
—
—
—
0
0
13
110
1.19
0.17
11.7
12.0
26.44
24.21
mmol/l
2.12
13
103
14
162
0.85
0.17
1.7
2.9
0.21
0.24
g/l
0.63
14
151
8
70
1.15
0.16
2.5
2.8
—
—
—
0
0
11
94
1.18
0.13
4.5
3.0
0.52
0.63
%
0.58
11
94
5
47
1.07
0.09
2.8
1.9
—
—
—
0
0
22
206
1.08
0.07
1.9
1.7
1081.37
1228.55
nmol/l
0.29
14
163
19
184
1.04
0.00
8.2
16.7
130.95
125.71
g/l
0.42
19
178
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
0.00
0.0
3.3
—
115.69
—
0
8
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
92
0.98
-0.00
1.2
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.1
—
999.33
—
0
9
0
6
0.00
-0.00
0.0
1.7
—
42.00
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.2
—
10.26
—
0
5
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
12
120
1.00
-0.00
1.7
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
91.14
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.2
—
4.76
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
-0.00
2.8
2.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_TESTICDYSNAS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_TESTICDYSNAS | 1.564 [1.05, 2.32] | 0.026 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 694 males with E4_TESTICDYSNAS died.
Mortality risk
Mortality risk for people of age
years, who have E4_TESTICDYSNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.294% |
| 5 | No data | 1.847% |
| 10 | No data | 4.324% |
| 15 | No data | 8.11% |
| 20 | No data | 13.644% |
Relationships between endpoints
↥Index endpoint: E4_TESTICDYSNAS – Testicular dysfunction, other/unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data